Sign In
Buy CRIS
$0.500
-0.0025 (-0.498%)
At Close: Jun 03, 2026
Curis (CRIS) Reports Q1 Loss, Tops Revenue Estimates
10:05am, Tuesday, 06'th May 2025
Curis (CRIS) came out with a quarterly loss of $1.25 per share versus the Zacks Consensus Estimate of a loss of $1.14. This compares to loss of $2.05 per share a year ago.
Curis Provides First Quarter 2025 Business Update
08:00am, Tuesday, 06'th May 2025
Curis strengthens executive team with the appointment of industry veteran Dr. Ahmed Hamdy as Chief Medical Officer Management to host conference call today at 8:30 a.m. ET LEXINGTON, Mass.
Curis to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on May 6, 2025
08:00am, Tuesday, 29'th Apr 2025
LEXINGTON, Mass. , April 29, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inh
Curis to Present at Upcoming Healthcare Conference in April
04:05pm, Wednesday, 02'nd Apr 2025
LEXINGTON, Mass. , April 2, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhi
Curis, Inc. (CRIS) Q4 2024 Earnings Call Transcript
09:59am, Monday, 31'st Mar 2025
Curis, Inc. (NASDAQ:CRIS ) Q4 2024 Earnings Conference Call March 31, 2025 8:30 AM ET Company Participants Diantha Duvall - CFO Jim Dentzer - President and CEO Jonathan Zung - Chief Development Office
Curis Provides Fourth Quarter 2024 Business Update
08:00am, Monday, 31'st Mar 2025
FDA and EMA discussions completed to support a potential accelerated approval path in both US and EU Orphan Drug Designation for PCNSL granted in both US and EU Management to host conference call toda
Curis to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on March 31, 2025
04:07pm, Friday, 28'th Mar 2025
LEXINGTON, Mass. , March 28, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inh
Curis Announces Additional Data from TakeAim Leukemia Study
08:00am, Tuesday, 10'th Dec 2024
LEXINGTON, Mass. , Dec. 10, 2024 /PRNewswire/ -- Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule
Curis, Inc. (CRIS) Q3 2024 Earnings Call Transcript
11:02am, Thursday, 14'th Nov 2024
Curis, Inc. (NASDAQ:CRIS ) Q3 2024 Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Diantha Duvall - Chief Financial Officer Jim Dentzer - President & Chief Executive Officer
Curis (CRIS) Reports Q3 Loss, Tops Revenue Estimates
10:10am, Thursday, 14'th Nov 2024
Curis (CRIS) came out with a quarterly loss of $1.70 per share versus the Zacks Consensus Estimate of a loss of $1.88. This compares to loss of $2.13 per share a year ago.
Curis Provides Third Quarter 2024 Business Update
08:00am, Thursday, 14'th Nov 2024
Management to host conference call today at 8:30 a.m. ET LEXINGTON, Mass.
Curis to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on November 14, 2024
08:00am, Thursday, 07'th Nov 2024
LEXINGTON, Mass. , Nov. 7, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhib
Curis Announces $12.1 Million Registered Direct and Concurrent Private Placement
06:04am, Tuesday, 29'th Oct 2024
LEXINGTON, Mass. , Oct. 29, 2024 /PRNewswire/ -- Curis, Inc. ("Curis") (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule
Curis Announces the 3rd Annual Symposium on IRAK4 in Cancer
08:30am, Monday, 23'rd Sep 2024
Symposium hosted by Eric S. Winer, MD, and Grzegorz S.
Curis to Participate at the Upcoming 2024 Cantor Fitzgerald Global Healthcare Conference
07:30am, Tuesday, 17'th Sep 2024
LEXINGTON, Mass. , Sept. 17, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inh
